Bellerophon Therapeutics (BLPH) News Today $0.04 0.00 (0.00%) (As of 11/4/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period StockNews.com Begins Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)October 31, 2024 | americanbankingnews.comAdocia SA (A89.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comBellerophon Therapeutics, Inc. (BLPH)February 25, 2024 | uk.finance.yahoo.comBellerophon Therapeutics Inc (BLPH)February 15, 2024 | investing.comBellerophon Offers Series A Stock in Private SaleJanuary 31, 2024 | msn.comHilco Streambank Seeks Offers to Acquire Patent Portfolio and Material Inventory of Biotherapeutics Company BellerophonNovember 28, 2023 | benzinga.comBellerophon Therapeutics Inc BLPHNovember 2, 2023 | morningstar.comBLPH - Bellerophon Therapeutics, Inc.August 8, 2023 | finance.yahoo.comWhat's Happening With Bellerophon Therapeutics Stock Today?July 25, 2023 | msn.comWhy Is Bellerophon Therapeutics (BLPH) Stock Down 34% Today?July 25, 2023 | investorplace.comBellerophon Therapeutics (BLPH) Price Target Decreased by 92.23% to 2.04July 6, 2023 | msn.comThe Latest Analyst Ratings for Bellerophon TherapeuticsJune 6, 2023 | markets.businessinsider.comIs Bellerophon Therapeutics (BLPH) Outperforming Other Medical Stocks This Year?June 6, 2023 | finance.yahoo.comLaidlaw & Co. Downgrades Bellerophon Therapeutics (BLPH)June 6, 2023 | msn.comHC Wainwright & Co. Maintains Bellerophon Therapeutics (BLPH) Buy RecommendationJune 6, 2023 | msn.comBellerophon Therapeutics Stock Nosedive: Here's WhyJune 5, 2023 | msn.comWhy Is Bellerophon Therapeutics (BLPH) Stock Down 79% Today?June 5, 2023 | msn.comBellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung DiseaseJune 5, 2023 | finance.yahoo.comTrading was temporarily halted for "BLPH" at 06:06 AM with a stated reason of "News pending."June 5, 2023 | marketbeat.comLucy Scientific, Bioventus top healthcare gainers; Enveric, Elevation among losersMay 19, 2023 | msn.comHC Wainwright Brokers Increase Earnings Estimates for Bellerophon Therapeutics, Inc. (NASDAQ:BLPH)Bellerophon Therapeutics, Inc. (NASDAQ:BLPH - Get Rating) - Stock analysts at HC Wainwright lifted their Q2 2023 EPS estimates for Bellerophon Therapeutics in a report released on Wednesday, May 17th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings perMay 19, 2023 | marketbeat.comBellerophon Therapeutics (NASDAQ:BLPH) delivers shareholders fantastic 978% return over 1 year, surging 18% in the last week aloneMay 17, 2023 | finance.yahoo.comBellerophon Therapeutics, Inc.: Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial ResultsMay 16, 2023 | finanznachrichten.deBellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial ResultsMay 15, 2023 | finance.yahoo.comBellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung DiseaseMay 11, 2023 | finance.yahoo.comBellerophon Therapeutics (BLPH) Outpaces Stock Market Gains: What You Should KnowApril 28, 2023 | finance.yahoo.comBellerophon (BLPH) to Report Q1 Earnings: What's in the Cards?April 24, 2023 | finance.yahoo.comBellerophon Therapeutics (BLPH) Dips More Than Broader Markets: What You Should KnowApril 19, 2023 | finance.yahoo.comBellerophon Therapeutics, Inc. (NASDAQ:BLPH) Short Interest Down 40.8% in MarchBellerophon Therapeutics, Inc. (NASDAQ:BLPH - Get Rating) saw a large decline in short interest in March. As of March 31st, there was short interest totalling 559,800 shares, a decline of 40.8% from the March 15th total of 945,100 shares. Based on an average trading volume of 1,210,000 shares, the days-to-cover ratio is presently 0.5 days.April 16, 2023 | marketbeat.comBellerophon Therapeutics (BLPH) Stock Sinks As Market Gains: What You Should KnowApril 13, 2023 | msn.comHC Wainwright & Co. Reiterates Bellerophon Therapeutics (BLPH) Buy RecommendationApril 4, 2023 | msn.comH.C. Wainwright Reaffirms Their Buy Rating on Bellerophon (BLPH)April 4, 2023 | markets.businessinsider.comWhen Will Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Turn A Profit?April 3, 2023 | finance.yahoo.comBellerophon Therapeutics GAAP EPS of -$2.08 misses by $0.06April 2, 2023 | seekingalpha.comBellerophon Therapeutics, Inc.: Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial ResultsMarch 31, 2023 | finanznachrichten.deBellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial ResultsMarch 31, 2023 | finance.yahoo.comBellerophon Therapeutics (BLPH) Is a Great Choice for 'Trend' Investors, Here's WhyMarch 28, 2023 | finance.yahoo.comHere's Why Momentum in Bellerophon Therapeutics (BLPH) Should Keep goingMarch 10, 2023 | finance.yahoo.comBellerophon to Buy Rival Firm’s SharesMarch 6, 2023 | baystreet.caBellerophon Therapeutics Surges 30% On Share Subscription Agreement With An Institutional InvestorMarch 6, 2023 | markets.businessinsider.comBellerophon Therapeutics Announces $5 Million Registered Direct OfferingMarch 6, 2023 | finance.yahoo.comBellerophon Therapeutics Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse® in Fibrotic Interstitial Lung DiseaseFebruary 9, 2023 | finance.yahoo.comBellerophon Therapeutics Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung DiseaseJanuary 18, 2023 | finance.yahoo.comHow Is The Market Feeling About Bellerophon Therapeutics?January 6, 2023 | benzinga.comShort Volatility Alert: Bellerophon TherapeuticsJanuary 6, 2023 | benzinga.comCompanies Like Bellerophon Therapeutics (NASDAQ:BLPH) Could Be Quite RiskyJanuary 6, 2023 | finance.yahoo.comBellerophon Therapeutics Shares Gained Over 200% TodayJanuary 5, 2023 | finance.yahoo.comBellerophon Therapeutics, Inc.: Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial ResultsNovember 14, 2022 | finanznachrichten.deBellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial ResultsNovember 14, 2022 | finance.yahoo.comBellerophon (BLPH) Receives FDA Acceptance to Reduce Study SizeSeptember 28, 2022 | finance.yahoo.com Get Bellerophon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BLPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Election warning coming true… (Ad)If you missed it, my emergency election broadcast is now available - watch it before it's too late. Click here to watch it now. BLPH Media Mentions By Week BLPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BLPH News Sentiment▼0.000.46▲Average Medical News Sentiment BLPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BLPH Articles This Week▼10▲BLPH Articles Average Week Get Bellerophon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BLPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Bionomics News Oragenics News Clever Leaves News ZyVersa Therapeutics News Altamira Therapeutics News Phio Pharmaceuticals News Peak Bio News Tharimmune News Psyence Biomedical News Cyclacel Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BLPH) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellerophon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bellerophon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
